The baby boom becomes the elder boom

In response to the high demand for healthcare professionals and over 2 million annual job openings — a 40% growth rate surpassing the average for all other occupations—healthcare organizations are seeking technological solutions to address this pressing issue.

Briana Contreras, an editor of Managed Healthcare Executive, spoke with Fred Turner, CEO of Curative, in this month’s episode about the challenges middle-class Americans face in dealing with medical debt, exploring the causes behind it and the impact on overall health.

The FDA has approved Lyfgenia and Casgevy to treat patients with sickle cell disease. Casgevy is the first FDA-approved gene therapy to use the CRISPR gene editing technology.

Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.

Leaders and clinicians say they are seeing better patient outcomes and a good return on their investments, according to a recent survey.

Zepbound, which was approved last month to treat obesity, is now available in U.S. pharmacies.